DURECT Corp. is a biopharmaceutical company focused on two areas of active drug development: New therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its epigenomic regulator program. Its drug development expertise is being applied primarily to the fields of pain management, central nervous system disorders, acute organ injury and metabolic diseases such as nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Late-stage development programs include POSIMIR (SABER-bupivacaine) and REMOXY (ORADUR-oxycodone). DURECT's epigenomic regulator program includes the lead molecule DUR-928 in Phase 1 development. DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival.

Expert Comments:

Four analysts provided updates regarding the status of this firm's financials and one of its clinical programs.
read more >
Ed Arce, H.C. Wainwright & Co. (3/6/18)
"Given our favorable view on the prospects of DURECT Corp.'s DUR-928 in primary sclerosing cholangitis (PSC) and multiple near-term catalysts, we raise our rating on the company's shares to Buy. . .we believe PSC, as an ultra-orphan disease with no approved therapies, represents a substantial commercial opportunity. . .our new price target is $3.50."

Francois Brisebois, Laidlaw & Company (3/2/18)
"With DURECT Corp.'s potential approval of its less abusable oxycodone extended release Remoxy (Aug. 7, 2018 PDUFA) and RBP-7000 (July 28, 2018), we continue to view 2018 as a crucial year at the company. . .we continue to see it as undervalued and reiterate our Buy rating and raise the price target from $2 to $2.50. . .we see as a real positive DURECT's multiple open-label trials as two of its three Phase 2 DUR-928 trials should have data readouts prior to 2018E."

Grant Zeng, Zacks Small-Cap Research (3/2/18)
"For Q4/17, DURECT Corp. recorded a total revenue of $19.5M, compared to $3.5M in the same period of last year. . .revenue from research and development collaborations was $16.3M in Q4/17, compared to $0.7M in the same period of 2016. . .product revenue, largely from the sale of Alzet pumps and Lactel polymers, was $3.3M in Q4/17, as compared to $2.8M in Q4/16." -Zacks Small-Cap Research

Patrick Dolezal, LifeSci Capital (2/27/18)
"DURECT Corp. announced the initiation of dosing in a Phase IIa trial for DUR-928 in the treatment of primary sclerosing cholangitis (PSC). . .KOL Dr. Keith Lindor, MD, who is Senior Advisor to the Provost at Arizona State University and a Professor of Medicine at Mayo Clinic, noted that he recently attended an endpoints workshop with the FDA, which had the goal of identifying potentially approvable endpoints for PSC. His take-away from the meeting was that non-invasive, non-biopsy based endpoints could likely be used for conditional approval (citing a paper that may be published in Hepatology soon)."

Patrick Dolezal, LifeSci Capital (12/13/17)
"Earlier today, DURECT Corp. announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application for Indivior's RBP-7000. . .the company is eligible for $5M upon FDA approval. . .the PDUFA date for RBP-7000 is July 28, 2018."

Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17.
read more >
Grant Zeng, Zacks Small-Cap Research (11/2/17)
"DURECT Corp. recorded a total revenue of $20.7M in Q3/17 ended Sept. 30, 2017, compared to $3.7M in Q3/16. . .the company reported net income of $6.1M in Q3/17, as compared to a net loss of $8.8M in Q3/16. At Sept. 30, it had cash and investments of $41.8M, which compared to $33.6M at June 30, 2017." -Zacks Small-Cap Research

A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.
read more >

More Expert Comments

Experts Following This Company

Ed Arce, Managing Direction and Senior Research Analyst – H.C. Wainwright & Co.
Francois Brisebois, Healthcare Research Analyst – Laidlaw & Company
Patrick Dolezal – LifeSci Capital
David Sherman, Analyst – LifeSci Capital
Adam Walsh, Analyst-Healthcare – Stifel
Grant Zeng, Senior Biotech Analyst – Zacks Investment Research, Zacks Small-Cap Research

The information provided above is from analysts, newsletters, the company and other contributors.

DURECT Corp. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
DUR-928, in Phase 1, is an Endogenous Small Molecule with Compelling Animal Data
Two Late Stage Pain Products Addressing Large Markets
Company Holds the WW Rights to DUR-928 and POSIMIR